Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Samantha Siva et al.|New England Journal of Medicine|2016Cited by 768
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Thesla Palanee‐Phillips et al.|Obstetrical & Gynecological Survey|2016Cited by 373
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension studyJared M. Baeten, Samuel Albert, Thesla Palanee‐Phillips et al.|The Lancet HIV|2021Cited by 111
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trialGonasagrie Nair, Kenneth Ngure, Connie Celum et al.|The Lancet HIV|2023Cited by 62
Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair ConcentrationsCatherine A. Koss, Monica Gandhi, Peter Bacchetti et al.|AIDS Research and Human Retroviruses|2017Cited by 57